La monitorización proactiva de niveles de anti-TNF mejora el seguimiento de los pacientes pediátricos con enfermedad de Crohn

Rodríguez Azor, Begoña; Martín-Masot, Rafael; Dayaldasani Khialani, Anita; Fernández-Martín, Jesús María; Gallego Fernández, Carmen; Navas-López, Víctor Manuel.
An. pediatr. (2003. Ed. impr.) ; 98(3): 165-174, mar. 2023. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-216876

Documentos relacionados

  1. Efficacy of infliximab after loss of response of/intolerance to adalimumab in pediatric Crohn's disease: A retrospective multicenter cohort study of the "GETAID pédiatrique".
  2. Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing.
  3. Adalimumab Therapy in Pediatric Crohn Disease: A 2-Year Follow-Up Comparing "Top-Down" and "Step-Up" Strategies.
  4. High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease.
  5. MIN score predicts primary response to infliximab/adalimumab and vedolizumab therapy in patients with inflammatory bowel diseases.
  6. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis.
  7. Combination biologic therapy in pediatric inflammatory bowel disease: Safety and efficacy over a minimum 12-month follow-up period.
  8. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
  9. Treatment of Ulcerative Colitis: Impact on Platelet Aggregation.
  10. The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn's Disease.